AUTHORS
Swetha Thiruvengadam, MD, Jomel Manzano2, Annie Xiao, MD3, Diamond Ward4, Nishita Matangi5, Brian Lee6, Stacy Pak, PharmD7, Murali Janakiram, MBBS8, Ryan Chiechi9, L. Elizabeth Elizabeth Budde, MD PhD10, Alexey V. Danilov, MD, PhD11, Alex Francisco Herrera, MD12, Myo Htut, MD13, Amrita Krishnan, MD, FACP14, Tycel Phillips, MD, FASCO15, Michael Rosenzweig, MD16, Tanya Siddiqi, MD17, Kimlin Ashing18, Lu Chen, PhD19, Betty Ferrell20, Nikhil Thiruvengadam21, Steven T Rosen, MD22
AFFILIATIONS
1 City of Hope National Medical Center, Duarte, United States
2 City of Hope National Medical Center, Duarte, United States
3 City of Hope National Medical Center, Duarte, United States
4 City of Hope National Medical Center, Duarte, United States
5 City of Hope National Medical Center, Duarte, United States
6 City of Hope National Medical Center, Duarte, United States
7 City of Hope National Medical Center, Duarte, United States
8 City of Hope National Medical Center, Duarte, United States
9 City of Hope National Medical Center, Duarte, United States
10 City of Hope National Medical Center, Duarte, United States
11 City of Hope National Medical Center, Duarte, United States
12 City of Hope National Medical Center, Duarte, United States
13 City of Hope National Medical Center, Duarte, United States
14 City of Hope National Medical Center, Duarte, United States
15 City of Hope National Medical Center, Duarte, United States
16 City of Hope National Medical Center, Duarte, United States
17 City of Hope National Medical Center, Duarte, United States
18 City of Hope National Medical Center, Duarte, United States
19 City of Hope National Medical Center, Duarte, United States
20 City of Hope National Medical Center, Duarte, United States
21 Loma Linda University, Loma Linda, United States
22 City of Hope National Medical Center, Duarte, United States
ABSTRACT
Background
Financial toxicity (FT) is defined as the negative financial consequences that pts and their families experience as a result of medical treatments. Time toxicity (TT) describes the significant time pts spend attending appointments, undergoing treatment, and managing side effects. Immunotherapies, such as bispecific antibodies (BsAbs) and chimeric antigen receptor T (CAR T) cell therapy, have transformed the treatment landscape of multiple myeloma (MM) and lymphoma but are associated with high costs. Furthermore, there are limited data on their FT and TT. This pilot study aims to capture the financial toxicity of these novel immunotherapies in lymphoma and MM pts.
Methods
We conducted a longitudinal prospective cohort study in which we enrolled pts initiating standard-of-care BsAbs or CAR T therapy.
Patient surveys were administered at baseline (within 30 days of CAR or first BsAbs infusion), 1 week, 1 month, 3 months, and 6 months after treatment initiation. We used the validated Comprehensive Score for Financial Toxicity (COST) to assess FT, using a validated cutoff for FT as a COST score less than the 18.5th percentile. Only patients who completed baseline and at least 2 additional follow-up timepoints were included in the analysis. TT was measured using physical days with healthcare system contact. Quality of Life (QoL) was measured using the FACT-G instrument, symptom burden was measured using the PRO-CTCAE Measurement System with the NCCN Distress Thermometer measuring psychological distress.
Results
We included 165 pts in the prospective cohort study (78 lymphoma, 85 MM), 133 of whom received CAR T (74 MM, 58 lymphoma) and 30 received BsAbs (11 MM, 19 lymphoma). The median age was 66 (range, 31-90), 61% were male, and 77% lymphoma pts had DLBCL. Regarding demographics, financial status, and employment, 66% were non-Hispanic white, 34% Hispanic, 8.8% Black or African American, and 11% Asian; 55% of pts had an annual household income below $75,000; 22.1% were currently employed, 35% were disabled, and 48% were retired.
Regarding FT, 64 (39%) reported it at baseline and only 20/64 (32%) had resolution of their FT during the 6 month period after treatment initiation. Factors that were associated with FT at baseline include: age < 65 (OR 3.11 95%-CI 1.62-6.06), Hispanic ethnicity (OR 2.27 95%-CI 1.64-6.64), being on short-term or long-term disability compared to currently working (OR 4.91 95%-CI 1.70-15.24), being divorced compared to currently married (OR 2.64 95%-CI 1.02-7.24), renting your home compared to ownership (OR 3.94 95%-CI 1.70-.48) and have a total income of less than $75,000 (OR 6.45 95%-CI 2.99-14.89).
Among 101 patients without baseline financial toxicity, 26/101 (26%) developed it at any timepoint in the 6 months following treatment initiation. Of these patients, 14/26 (54%) had recovered at their last timepoint of follow-up.
Comparing CAR and BsAbs, 37% of the patients who received CAR T had baseline FT and 25% developed new FT, while 47% of pts who received BsAbs had baseline FT and 19% developed new FT.
Regarding TT, pts reported a mean of 3.24 ± 2.01 days of health system contact per week at baseline, 5.42 ± 2.41 at 1 week, 2.32 ± 1.70 at 1 mos, 1.69 ± 1.58 at 3 mos, and 1.24 ± 1.35 at 6 mos.
Baseline FT was moderately correlated with lower QoL, higher psychological distress, and higher symptom burden (p<0.05). Baseline TT showed weak, non-significant associations with all three (p>0.05), suggesting TT may not be as strongly linked to these outcomes at baseline.
Conclusions
Our preliminary results demonstrate that almost 40% of patients have baseline FT before starting BsAbs or CAR T therapy, with more than two-thirds having persistent FT after receipt of therapy. Furthermore, 26% develop new FT after BsAbs/CAR T therapy, with only 54% having resolution of their FT. There were also high rates of TT after receipt of therapy. Both FT and TT were associated with lower QoL and higher rates of psychological distress and symptom burden. These data highlight the importance of screening for financial distress before starting these therapies, with targeted intervention to address FT from prior lines of therapy, while close monitoring for FT/TT/symptom burden after therapy initiation to intervene and improve psychological distress and quality of life for patients requiring T-cell-engaging therapies.
DISCLOSURES
Swetha Thiruvengadam, MD: Innate Pharma SA - Honoraria; ADC Therapeutics - Research Funding; Genmab - Research Funding; Genentech - Research Funding; Innate Pharma SA - Consultancy (Includes expert testimony)